(Q37489181)

20 August 2017

1 reference

title

Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up (English)

1 reference

ESMO Guidelines Working Group

20 August 2017

0 references

1 reference

V Kataja

2

0 references

series ordinal

3

object named as

ESMO Guidelines Working Group

1 reference

20 August 2017

B Escudier

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

20 Suppl 4

1 reference

20 August 2017

page(s)

81-82

1 reference

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP137

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP137

1 reference

20 August 2017

1 reference